基于嵌合抗原的禽流感纳米疫苗在禽类中的有效保护
禽流感病毒危害家禽并具大流行潜力,现有疫苗免疫原性与广谱性不足。研究开发H5嵌合血凝素(H5M)抗原,分别用改良痘苗病毒安卡拉株(MVA)载体递送或聚酸酐纳米颗粒(PAN)包封,在SPF鸡与商品鸡中均诱导体液和细胞免疫,免疫后8周可抵御低致病性禽流感病毒攻击并减少排毒,对H5N1和H5N2高致病性禽流感亦产生保护性体液免疫。
要点
- H5M抗原经MVA载体或PAN包封递送均具免疫原性。
- 免疫鸡在8周后抵御LPAI攻击并减少病毒排毒。
- 对H5N1与H5N2高致病性禽流感产生保护性抗体。
核心结论
- MVA载体与PAN包封的H5M疫苗平台在鸡中安全并提供高水平持续保护。
研究设计与样本
- 开发H5嵌合血凝素(H5M)抗原,分别用MVA载体递送或PAN包封,在SPF鸡和商品鸡中评估免疫原性与保护效果。
主要发现
- H5M疫苗构建体经MVA或PAN递送后,在SPF鸡和商品鸡中均诱导体液和细胞免疫应答。
- 免疫后8周,接种鸡抵御低致病性禽流感(LPAI)株攻击并减少病毒排毒。
- 对相似H5N1和遗传差异较大的H5N2高致病性禽流感病毒产生保护性水平体液免疫。
临床怎么用
- 该平台技术可用于设计更有效的禽类疫苗,以防控禽流感和其他重要家禽感染。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Avian influenza virus (AIV) is an extraordinarily diverse pathogen that causes significant morbidity in domesticated poultry populations and threatens human life with looming pandemic potential. Controlling avian influenza in susceptible populations requires highly effective, economical and broadly reactive vaccines. Several AIV vaccines have proven insufficient despite their wide use, and better technologies are needed to improve their immunogenicity and broaden effectiveness. Previously, we developed a "mosaic" H5 subtype hemagglutinin (HA) AIV vaccine and demonstrated its broad protection against diverse highly pathogenic H5N1 and seasonal H1N1 virus strains in mouse and non-human primate models. There is a significant interest in developing effective and safe vaccines against AIV that cannot contribute to the emergence of new strains of the virus once circulating in poultry. Here, we report on the development of an H5 mosaic (H5M) vaccine antigen formulated with polyanhydride nanoparticles (PAN) that provide sustained release of encapsulated antigens. H5M vaccine constructs were immunogenic whether delivered by the modified virus Ankara (MVA) strain or encapsulated within PAN. Both humoral and cellular immune responses were generated in both specific-pathogen free (SPF) and commercial chicks. Importantly, chicks vaccinated by H5M constructs were protected in terms of viral shedding from divergent challenge with a low pathogenicity avian influenza (LPAI) strain at 8 weeks post-vaccination. In addition, protective levels of humoral immunity were generated against highly pathogenic avian influenza (HPAI) of the similar H5N1 and genetically dissimilar H5N2 viruses. Overall, the developed platform technologies (MVA vector and PAN encapsulation) were safe and provided high levels of sustained protection against AIV in chickens. Such approaches could be used to design more efficacious vaccines against other important poultry infections.
引用
- Kingstad-Bakke BA, Chandrasekar SS, Phanse Y, et al. Effective mosaic-based nanovaccines against avian influenza in poultry. Vaccine. 2019. PMID: 31300285. doi:10.1016/j.vaccine.2019.06.077
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。